Categories Analysis, Earnings, Energy, U.S. Markets News
JinkoSolar Q3 2018 earnings fall short of market expectations
Chinese solar giant JinkoSolar (JKS) saw third-quarter revenue grow 4.3% to $974.8 million, pushing net profit to $27.5 million or $0.18 per share, as it posted its results before opening bell on Monday, Nov. 26. However, this fell below market expectations — analysts were looking for earnings of $0.61 a share on revenue of $989 million for the three-month period.
The quarter saw total solar module shipments of 2,953 MW, including 0.2 MW to the JinkoSolar’s overseas downstream segment.
As of September 30, 2018, JinkoSolar’s in-house annual silicon wafer, solar cell and solar module production capacity were 9.2 GW, 6.5 GW and 10.0 GW, respectively.
JinkoSolar now expects fourth-quarter total solar module shipments to be in the range of 3.7 GW to 4.0 GW. For the full year 2018, the Chinese firm estimates total solar module shipments to be in the range of 11.5 GW to 11.8 GW.
Back in August, JinkoSolar had slipped as much as 27% in trade on the day it posted second-quarter results. Investors were not happy with the numbers they say, even as shipments jumped 38.7% to 2,794 MW and revenue soared 32.7% to $915.9 million.
However, earlier this month, JinkoSolar shares jumped 16.5% after reports of a reversal in policy back in China that would benefit solar firms. Earlier, the Chines govt had suggested that further production of panels might go down as it achieved targets. However, recent findings suggest that the targets may be ramped up to more than twice the initiation projection. Shares moved on the hope that the Chinese government may raise the solar capacity goal of 2020 to 210-270 gigawatts.
JinkoSolar, with institutions on the share registry who own 21% share liking the stock, there is hope for the solar company to do good in the long term. While risks of a ‘crowded trade’ are high in such a stock, let’s see how the solar industry performs from this quarter.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on